Current Hepatitis Reports

, Volume 12, Issue 3, pp 143–148 | Cite as

The Evolution of HCV Treatment in Taiwan

Global Perspectives: Taiwan and Asia (ML Yu and RN Chien, Section Editors)

Abstract

The treatment strategies used in Taiwan for patients with chronic hepatitis C (CHC) have evolved from conventional interferon monotherapy, consensus interferon therapy, conventional interferon/ribavirinand to pegylated interferon/ribavirin combination therapy. In the past two decades, the sustained virological response (SVR) rate in Taiwanese patients improved from 6 to 75-90 %. By following genotype-guided therapy, an SVR rate of 75-80 % and 85-95 % could be achieved in Taiwanese patients with HCV-1 and HCV-2 infections, respectively. The study of HCV viral kinetics has facilitated studies in Taiwan regarding response-guided therapy with tailored regimens. The majority of Taiwanese patients can be treated successfully with pegylated interferon/ribavirin. The application of IL-28B genetic tests and the insight provided by the viral kinetics might aid in selecting the best candidates for treatment with direct antivirals in the near future in Taiwan.

Keywords

HCV Treatment Taiwan 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Hanafiah KM, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to hepatitis C virus seroprevalence. Hepatology. 2013;57(4):1333–42.CrossRefGoogle Scholar
  2. 2.
    Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol. 2009;24:336–45.PubMedCrossRefGoogle Scholar
  3. 3.
    Chen CH, Yang PM, Huang GT, Lee HS, Sung JL, Sheu JC. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Asso = Taiwan yi zhi. 2007;106:148–55.CrossRefGoogle Scholar
  4. 4.
    Chuang WL, Yu ML, Dai CY, Chang WY. Treatment of chronic hepatitis C in southern Taiwan. Intervirology. 2006;49:99–106.PubMedCrossRefGoogle Scholar
  5. 5.
    Wu JS, Lu CF, Chou WH, et al. High prevalence of hepatitis C virus infection in aborigines in Taiwan. Jpn J Med Sci Biol. 1992;45:165–74.PubMedGoogle Scholar
  6. 6.
    Lu SN, Chue PY, Chen HC, et al. Different viral aetiology of hepatocellular carcinoma between two hepatitis B and C endemic townships in Taiwan. J Gastroenterol Hepatol. 1997;12:547–50.PubMedCrossRefGoogle Scholar
  7. 7.
    Wang JH, Lu SN, Wu JC, et al. A hyperendemic community of hepatitis B virus and hepatitis C virus infection in Taiwan. T Roy Soc Trop Med H. 1999;93:253–4.CrossRefGoogle Scholar
  8. 8.
    Wang CS, Chang TT, Yao WJ, Chou P. Comparison of hepatitis B virus and hepatitis C virus prevalence and risk factors in a community-based study. AmJTrop Med Hyg. 2002;66:389–93.Google Scholar
  9. 9.
    Huang CF, Huang JF, Dai CY, et al. Changing prevalence of hepatitis C virus infection among teenagers in an endemic area in Taiwan. T Roy Soc Trop Med H. 2008;102:929–34.CrossRefGoogle Scholar
  10. 10.
    Yang JF, Lin CI, Huang JF, et al. Viral hepatitis infections in southern Taiwan: a multicenter community-based study. Kaohsiung J Med Sci. 2010;26:461–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Dai CY, Ho CK, Huang JF, et al. Hepatitis C virus viremia and low platelet count: a study in a hepatitis B & C endemic area in Taiwan. J Hepatol. 2010;52:160–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Hwang SJ, Chan CY, Lu RH, Wu JC, Lee SD. Randomized controlled trial of recombinant interferon-alpha 2b in the treatment of Chinese patients with chronic hepatitis C. J Interf Cytok Res. 1995;15:611–6.CrossRefGoogle Scholar
  13. 13.
    Lai MY, Kao JH, Yang PM, et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology. 1996;111:1307–12.PubMedCrossRefGoogle Scholar
  14. 14.
    Yu ML, Dai CY, Chen SC, et al. High versus standard doses interferon-alpha in the treatment of naive chronic hepatitis C patients in Taiwan: a 10-year cohort study. BMC Infect Dis. 2005;5:27.PubMedCrossRefGoogle Scholar
  15. 15.
    Yu ML, Dai CY, Chen SC, et al. A prospective study on treatment of chronic hepatitis C with tailored and extended interferon-alpha regimens according to pretreatment virological factors. Antiviral Res. 2004;63:25–32.PubMedCrossRefGoogle Scholar
  16. 16.
    Hwang SJ, Lee SD, Chan CY, Lu RH, Chang FY. A randomized, double-blind, controlled trial of consensus interferon in the treatment of Chinese patients with chronic hepatitis C. Am J Gastroenterol. 1999;94:2496–500.PubMedCrossRefGoogle Scholar
  17. 17.
    Kao JH, Chen PJ, Lai MY, Chen DS. Efficacy of consensus interferon in the treatment of chronic hepatitis C. J Gastroenterol Hepatol. 2000;15:1418–23.PubMedCrossRefGoogle Scholar
  18. 18.
    Hwang S, Lee S, Chu C, Lu R, Chang F. An open-label trial of consensus interferon 15 microg in the treatment of Chinese patients with chronic hepatitis C. Hepatol Res. 2001;19:284–93.PubMedCrossRefGoogle Scholar
  19. 19.
    Lee SD, Yu ML, Cheng PN, et al. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat. 2005;12:283–91.PubMedCrossRefGoogle Scholar
  20. 20.
    Liu CJ, Chen PJ, Lai MY, Kao JH, Jeng YM, Chen DS. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology. 2003;37:568–76.PubMedCrossRefGoogle Scholar
  21. 21.
    Hung CH, Lee CM, Lu SN, et al. Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. J Gastroenterol Hepatol. 2005;20:727–32.PubMedCrossRefGoogle Scholar
  22. 22.
    Yu ML, Dai CY, Lee LP, et al. A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels. Liver Int. 2006;26:1187–95.PubMedCrossRefGoogle Scholar
  23. 23.
    Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology. 2008;47:1884–93.PubMedCrossRefGoogle Scholar
  24. 24.
    Liu CH, Liu CJ, Lin CL, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis. 2008;47:1260–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Chu CJ, Wang YJ, Hwang SJ, et al. Kinetics of hepatitis C virus RNA load during pegylated interferon plus ribavirin therapy in Treatment-naive Chinese patients. Hepato-Gastroenterology. 2007;54:866–70.PubMedGoogle Scholar
  26. 26.
    Chen LW, Chien RN, Yen CL, Chang JJ, Liu CJ, Lin CL. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection. J Gastroenterol Hepatol. 2010;25:259–63.PubMedCrossRefGoogle Scholar
  27. 27.
    Su WP, Peng CY, Lai HC, et al. Persistent transaminase elevations in chronic hepatitis C patients with virological response during peginterferon and ribavirin therapy. Hepato-Gastroenterology. 2009;56:798–801.PubMedGoogle Scholar
  28. 28.
    Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut. 2007;56:553–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Liu CJ, Chuang WL, Lee CM, et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology. 2009;136:496–504 e3.PubMedCrossRefGoogle Scholar
  30. 30.
    Hadziyannis SJ, Sette Jr H, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–55.PubMedCrossRefGoogle Scholar
  31. 31.
    Craxi A. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol. 2011;55:245–64.CrossRefGoogle Scholar
  32. 32.
    Omata M, Kanda T, Yu M-L, et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int. 2012;6:409–35.CrossRefGoogle Scholar
  33. 33.
    Yu ML, Dai CY, Lin ZY, et al. A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan. Liver Int. 2006;26:73–81.PubMedCrossRefGoogle Scholar
  34. 34.
    Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol. 2011;55:69–75.PubMedCrossRefGoogle Scholar
  35. 35.
    Yu ML, Chuang WL, Dai CY, et al. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy. Transl Res. 2006;148:120–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Yu ML, Dai CY, Lee LP, et al. Outcome of chronic hepatitis C patients who required early termination of pegylated interferon-alpha plus ribavirin combination therapy. Antivir Ther. 2006;11:1015–9.PubMedGoogle Scholar
  37. 37.
    Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003;38:645–52.PubMedCrossRefGoogle Scholar
  38. 38.
    Hung CH, Lee CM, Lu SN, et al. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat. 2006;13:409–14.PubMedCrossRefGoogle Scholar
  39. 39.
    • Huang JF, Yu ML, Huang CF, et al. The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis C patients with hepatocellular carcinoma post curative therapies - a multicenter prospective trial. J Hepatol. 2011;54:219–26. Cirrhotic patients with hepatocellular carcinoma post curative therapies might have a satisfactory SVR rate particularly if they are infected with HCV-2.PubMedCrossRefGoogle Scholar
  40. 40.
    Kao JH, Chen PJ, Lai MY, Chen DS. Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol. 2002;40:4068–71.PubMedCrossRefGoogle Scholar
  41. 41.
    Chuang WL, Dai CY, Chang WY, et al. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy. Antivir Ther. 2005;10:125–33.PubMedGoogle Scholar
  42. 42.
    Chuang WL, Yu ML. Host factors determining the efficacy of hepatitis C treatment. J Gastroenterol. 2013;48:22–30.PubMedCrossRefGoogle Scholar
  43. 43.
    • Huang CF, Dai CY, Huang JF, Chuang WL, Yu ML. Linkage of the hepatitis C virus genotype and interleukin-28B genetic polymorphisms in Asian patients. Hepatology. 2011;53:367–8. author reply 8. A higher proportion of favorable IL-28B genotype carriage in HCV-2 patients might account for higher SVR rate.PubMedCrossRefGoogle Scholar
  44. 44.
    Liu CH, Liang CC, Liu CJ, et al. Interleukin 28B genetic polymorphisms and viral factors help identify hepatitis C virus genotype 1 patients who benefit from 24 week of peginterferon plus ribavirin therapy. Antivir Ther. 2012;17:477–84.PubMedCrossRefGoogle Scholar
  45. 45.
    Huang CF, Huang JF, Yang JF, et al. Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. J Hepatol. 2012;56:34–40.PubMedCrossRefGoogle Scholar
  46. 46.
    Huang CF, Yeh ML, Huang JF, et al. Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard–of-care for Asians with hepatitis C genotype 1. Antiviral Res. 2012;93:239–44.PubMedCrossRefGoogle Scholar
  47. 47.
    Hsu CS, Hsu SJ, Chen HC, et al. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc Natl Acad Sci U S A. 108: 3719-24.Google Scholar
  48. 48.
    Lin CY, Chen JY, Lin TN, et al. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS One. 2011;6, e18322.PubMedCrossRefGoogle Scholar
  49. 49.
    Chen JY, Lin CY, Wang CM, et al. IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-alpha plus ribavirin therapy in Taiwanese chronic HCV infection. Genes Immun. 2011;12:300–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Liu CH, Liang CC, Liu CJ, et al. Interleukin 28B genetic polymorphisms play a minor role to identify the optimal treatment duration in hepatitis C virus genotype 1 non rapid viral responders to peginterferon plus ribavirin. Antivir Ther. 2012;17:1059–67.PubMedCrossRefGoogle Scholar
  51. 51.
    Schreiber J, Moreno C, Garcia BG, et al. Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and -3 patients. Aliment Pharmacol Ther. 2012;36:353–62.PubMedCrossRefGoogle Scholar
  52. 52.
    Jeng WJ, Lin CY, Chen JY, Huang CW, Huang CH, Sheen IS. None of the six SNPs of IL28B could predict treatment responses in genotype 2 chronic HCV infected patients by propensity score matching analysis. PLoS One. 2012;7, e48217.PubMedCrossRefGoogle Scholar
  53. 53.
    • Yu ML, Huang CF, Huang JF, et al. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology. 2011;53:7–13. Host-IL28B genetic variants play limited role in Taiwanese HCV-2 patients. The only determinant for an SVR was the achievement of a RVR in the 482 -patient cohort.PubMedCrossRefGoogle Scholar
  54. 54.
    Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433–44.PubMedCrossRefGoogle Scholar
  55. 55.
    Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med. 2012;156:279–90.PubMedCrossRefGoogle Scholar
  56. 56.
    • Yu ML, Liu CH, Huang CF, et al. Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin. PLoS One. 2012;7, e52048. HCV-1 Taiwanese patients with HCV RNA <1 log IU/mL reduction or IL-28B unfavorable genotype carriers with HC V RNA >10,000 IU/mL at week 4 of peginterferon/ribavirin therapy had nealy no chance for cure and should be considered to stop treatment early an wait for DAAs.PubMedCrossRefGoogle Scholar
  57. 57.
    • Huang CF, Yu ML, Kao JH, et al. Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype. J Clin Virol. 2013;56(4):293–8. Only 1 of the 10 IL-28B unfavorable genotype carriers could have SVR after 48 weeks of peginterferon/ribavirin if they fail to have a decline HCV RNA of > 3 log IU/mL at week 4 of treatment.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Chung-Feng Huang
    • 1
    • 2
    • 3
  • Wan-Long Chuang
    • 2
    • 4
  • Ming-Lung Yu
    • 2
    • 4
  1. 1.Institute of Clinical Medicine, College of MedicineKaohsiung Medical UniversityKaohsiungTaiwan
  2. 2.Hepatobiliary Division, Department of Internal Medicine and Hepatitis CenterKaohsiung Medical University HospitalKaohsiungTaiwan
  3. 3.Department of Occupational Medicine, Kaohsiung Municipal Ta-Tung HospitalKaohsiung Medical University Hospital, Kaohsiung Medical UniversityKaohsiungTaiwan
  4. 4.Faculty of Internal Medicine, School of Medicine, College of MedicineKaohsiung Medical UniversityKaohsiungTaiwan

Personalised recommendations